Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pseudomonas Infections 1Pneumonia 1Hematologic Neoplasms 1Gram-Negative Bacterial Infections 1Bacteremia 1

Interventions

pembrolizumab 311Nivolumab 159Carboplatin 158Cisplatin 140Cyclophosphamide 135Paclitaxel 129Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 93Gemcitabine 88Dexamethasone 86Biopsy 81Ipilimumab 81Docetaxel 78Doxorubicin 77Rituximab 71Etoposide 69durvalumab 62Lenalidomide 61Radiation 61atezolizumab 60Prednisone 59Pemetrexed 58Taxes 58Bevacizumab 55fludarabine 54olaparib 53Vincristine 52Cytarabine 51Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ceftolozane, tazobactam drug combination × 1 year × Clear all
NCT04673175 2026-01-21

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Weill Medical College of Cornell University

Phase 4 Terminated
17 enrolled 20 charts
Other hematologic neoplasm

Pneumonia, Pseudomonas Infections, Bacteremia, Gram-Negative Bacterial Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡